Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation


Genexine to concentration on world drug improvement and commercialization

– In the vicinity of time period milestones really should push shareholder benefit

– Renewed effort and hard work to extend pipeline with an emphasis on novel, differentiated products

SEOUL, South Korea, Could 25, 2022–(Organization WIRE)–Genexine (KOSDAQ: 095700) a publicly traded, scientific phase biopharmaceutical firm committed to the discovery and enhancement of novel biologics for the treatment method of unmet health-related needs, announced the appointment of Neil Warma as its President and Main Executive Officer. Mr. Warma who has over 25 several years of encounter as a international entrepreneur, enterprise builder and effective CEO will direct Genexine onto the planet stage with a aim on advancing Genexine’s vital items to industry, increasing its pipeline and focusing on global drug enhancement.

Mr. Warma has been a productive healthcare entrepreneur for more than 25 yrs getting led and managed several biotechnology and pharmaceutical providers across the globe. From 2019-2022, Mr. Warma was the Common Supervisor of I-Mab Biopharma U.S., (Nasdaq:IMAB) with places of work in Shanghai, Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego, in the U.S., where by he was a member of the govt crew accountable for the Company’s growth onto the world-wide phase and for creating I-Mab’s condition-of-the-art investigate facilities in San Diego, California. From 2008-2017, Mr. Warma was President, CEO and Director of Opexa Therapeutics, Inc. (Nasdaq:OPXA), a publicly traded biopharmaceutical firm producing novel cellular therapies for the treatment of autoimmune illnesses, the place he orchestrated world wide deals with Novartis and Merck Serono. From 2004-2007, he was President, CEO and Director of Viron Therapeutics, a personal biotechnology organization creating novel protein-dependent therapeutics for cardiovascular ailment and transplantation. In 2000, Mr. Warma co-established and afterwards bought MedExact, a health-technological innovation corporation committed to providing an interface among medical professionals and pharmaceutical businesses. From 1992-2000, Mr. Warma held a number of key senior management roles at Novartis Pharmaceuticals at its company headquarters in Basel, Switzerland, in Pharma Coverage and Worldwide Promoting. Mr. Warma attained an honors Bachelor of Science degree specializing in neuroscience from the University of Toronto and an Intercontinental MBA from the Schulich School of Small business at York University in Toronto. Mr. Warma currently serves on the Board of ProMIS Neurosciences (TSX:PMN) and the Biotechnology Innovation Business (BIO). Mr. Warma has also been a member of the Board of Directors of Genexine considering that March 2021 and will go on to provide on the Board as an Government Director.

“I am deeply honored to have been selected as Genexine’s new CEO by the Board of Administrators,” stated Mr. Warma. “The Organization has developed a powerful scientific basis based mostly on novel science and differentiated technological innovation more than quite a few years. My focus will be to commercialize present late stage goods and further extend Genexine’s pipeline of existence-preserving solutions with a focus on initial and finest-in-class items. We will not only leverage our energy and placement as a major Korean biopharmaceutical enterprise but will also increase our get to into the U.S. and Europe to improve our shareholder foundation and access new technological know-how and major talent. Genexine has an interesting pipeline and with its global companions is conducting more than 20 medical trials, quite a few in Section 3 registrational trials. We be expecting to file quite a few crucial BLAs in the future 1-3 years and commercialize our 1st merchandise soon thereafter.”

“My purpose is to introduce the biotech world to the leading-class technologies we have created in Korea such that we can leverage our clinical data in the US and EU to minimize our improvement fees and pace the supply of our solutions to the patient. We will also look to safe partnerships with world wide multinational pharmaceutical partners to share fees and leverage their sizeable knowledge. We are energized to be reporting some close to phrase milestones coming up around the subsequent many months with the prepared announcement of Stage 1b/2 clinical data in our prospective blockbuster solution, GX-I7, the extended-acting recombinant Interleukin-7 protein and Phase 2 details in our to start with-in-course DNA cancer vaccine remaining researched in cervical and head and neck cancers. These close to time period milestones really should display our ability to execute and advance our products toward the market and, in the long run, to the affected individual,” included Mr. Warma.

About Genexine

Genexine, Inc. is a publicly traded, medical-stage biotechnology company concentrated on the growth and commercialization of immunotherapeutics and next-generation lengthy-performing biologics. Its primary technology platforms are Therapeutic DNA vaccine technological know-how and hyFc™ fusion technology. The Business has a number of items in scientific improvement including numerous undergoing Period 3 registrational trials. The Company’s proprietary pipeline involves GX-188 for cervical and head and neck cancers. GX-I7 for many cancers, GX-H9 for Pediatric Expansion Hormone Deficiency, and GX-E4 for CKD-induced anemia, between many others. Genexine has established various partnerships with world-wide firms in purchase to expedite product or service improvement and commercialization and generate considerable value. Genexine is mentioned on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is fully commited to the very well-becoming and care of patients globally.

Watch supply variation on


Mr. Jongsoo Lee
Trader Relations, Genexine, Inc.
[email protected]


Source connection